Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. Among authors: arance a. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: arance a. Ann Surg Oncol. 2024 Nov;31(12):8262-8263. doi: 10.1245/s10434-024-15886-6. Ann Surg Oncol. 2024. PMID: 39026142 Free PMC article. No abstract available.
Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.
Gaudy-Marqueste C, Grob JJ, Garbe C, Ascierto PA, Arron S, Basset-Seguin N, Bohne AS, Lenoir C, Dummer R, Fargnoli MC, Guminski A, Hauschild A, Kaufmann R, Lallas A, Del Marmol V, Migden M, Penicaud M, Rembielak A, Stratigos A, Tagliaferri L, Zalaudek I, Arance A, Badinand D, Bossi P, Challapalli A, Clementi M, Di Stefani A, Ferrándiz-Pulido C, Giuffrida R, Gravina GL, Ha P, Heinzerling L, Mallet S, Paradisi A, Mohr P, Piccerillo A, Rutkowski D, Saiag P, Sollena P, Trakatelli M, Wojcieszek P, Yom SS, Zelin E, Peris K, Malvehy J. Gaudy-Marqueste C, et al. Among authors: arance a. J Eur Acad Dermatol Venereol. 2024 Jul 3. doi: 10.1111/jdv.20209. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38961704
[No title available]
[No authors listed] [No authors listed] PMID: 38789613
Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.
Castrejon N, Martin R, Carrasco A, Castillo P, Garcia A, Albero-González R, García M, Marginet M, Palau N, Hernández M, Montironi C, Clot G, Arance A, Alos L, Teixido C. Castrejon N, et al. Among authors: arance a. Int J Mol Sci. 2024 Jun 25;25(13):6942. doi: 10.3390/ijms25136942. Int J Mol Sci. 2024. PMID: 39000050 Free PMC article.
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR. Robert C, et al. Among authors: arance a. Lancet Oncol. 2013 Jul;14(8):733-40. doi: 10.1016/S1470-2045(13)70237-7. Epub 2013 Jun 2. Lancet Oncol. 2013. PMID: 23735514 Clinical Trial.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Larkin J, et al. Among authors: arance a. Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27. Lancet Oncol. 2014. PMID: 24582505 Clinical Trial.
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O, Ilaria R Jr, Garbe C, Wolter P, Maio M, Hutson TE, Arance A, Lorigan P, Lee J, Hauschild A, Mohr P, Hahka-Kemppinen M, Kaiser C, Turner PK, Conti I, Grob JJ. Hamid O, et al. Among authors: arance a. Cancer. 2014 Jul 1;120(13):2016-24. doi: 10.1002/cncr.28635. Epub 2014 Mar 26. Cancer. 2014. PMID: 24676877 Free article. Clinical Trial.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Long GV, et al. Among authors: arance a. N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29. N Engl J Med. 2014. PMID: 25265492 Free article. Clinical Trial.
135 results